Inflammation is genetically implicated in Parkinson's disease

Neuroscience

Volumn 302, Issue , 2015, Pages 89-102

  Dzamko, N ^a,b   Geczy, C L ^a   Halliday, G M ^a,b  

^a UNIVERSITY OF NEW SOUTH WALES   (Australia)

^b NEUROSCIENCE RESEARCH AUSTRALIA   (Australia)

Author keywords

Inflammation; Innate; LRRK2; Parkin; Synuclein; TLR

Indexed keywords

ALPHA SYNUCLEIN; DJ 1 PROTEIN; GLUCOSYLCERAMIDASE; LEUCINE RICH REPEAT KINASE 2; PARKIN; CYTOKINE; REACTIVE OXYGEN METABOLITE; TOLL LIKE RECEPTOR;

DJ 1 GENE; GBA GENE; GENE FUNCTION; GENE LOCUS; GENETIC ANALYSIS; GENETIC ASSOCIATION; GENETIC CODE; GENETIC RISK; GENETIC VARIABILITY; HUMAN; INFLAMMATION; LRRK2 GENE; MARKER GENE; MISSENSE MUTATION; MITOCHONDRION; NONHUMAN; PARKIN GENE; PARKINSON DISEASE; PINK1 GENE; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; SIGNAL TRANSDUCTION; SNCA GENE; ANIMAL; COMPLICATION; GENETICS; METABOLISM;

ANIMALS; CYTOKINES; HUMANS; INFLAMMATION; PARKINSON DISEASE; REACTIVE OXYGEN SPECIES; TOLL-LIKE RECEPTORS;

EID: 84938221814     PISSN: 03064522     EISSN: 18737544     Source Type: Journal    
DOI: 10.1016/j.neuroscience.2014.10.028     Document Type: Review

References (185)

1. Ahmed I., Tamouza R., Delord M., Krishnamoorthy R., Tzourio C., Mulot C., Nacfer M., Lambert J.C., Beaune P., Laurent-Puig P., Loriot M.A., Charron D., Elbaz A. Association between Parkinson's disease and the HLA-DRB1 locus. Mov Disord 2012, 27:1104-1110.
2. Akundi R.S., Huang Z., Eason J., Pandya J.D., Zhi L., Cass W.A., Sullivan P.G., Bueler H. Increased mitochondrial calcium sensitivity and abnormal expression of innate immunity genes precede dopaminergic defects in Pink1-deficient mice. PloS One 2011, 6:e16038.
3. Alvarez-Erviti L., Couch Y., Richardson J., Cooper J.M., Wood M.J. Alpha-synuclein release by neurons activates the inflammatory response in a microglial cell line. Neurosci Res 2011, 69:337-342.
4. Baba Y., Kuroiwa A., Uitti R.J., Wszolek Z.K., Yamada T. Alterations of T-lymphocyte populations in Parkinson disease. Parkinsonism Relat Disord 2005, 11:493-498.
5. Bandopadhyay R., Kingsbury A.E., Cookson M.R., Reid A.R., Evans I.M., Hope A.D., Pittman A.M., Lashley T., Canet-Aviles R., Miller D.W., McLendon C., Strand C., Leonard A.J., Abou-Sleiman P.M., Healy D.G., Ariga H., Wood N.W., de Silva R., Revesz T., Hardy J.A., Lees A.J. The expression of DJ-1 (PARK7) in normal human CNS and idiopathic Parkinson's disease. Brain 2004, 127:420-430.
6. Benner E.J., Banerjee R., Reynolds A.D., Sherman S., Pisarev V.M., Tsiperson V., Nemachek C., Ciborowski P., Przedborski S., Mosley R.L., Gendelman H.E. Nitrated alpha-synuclein immunity accelerates degeneration of nigral dopaminergic neurons. PloS One 2008, 3:e1376.
7. Bessler H., Djaldetti R., Salman H., Bergman M., Djaldetti M. IL-1 beta, IL-2, IL-6 and TNF-alpha production by peripheral blood mononuclear cells from patients with Parkinson's disease. Biomed Pharmacother 1999, 53:141-145.
8. Blum-Degen D., Muller T., Kuhn W., Gerlach M., Przuntek H., Riederer P. Interleukin-1 beta and interleukin-6 are elevated in the cerebrospinal fluid of Alzheimer's and de novo Parkinson's disease patients. Neurosci Lett 1995, 202:17-20.
9. Bonifati V., Rizzu P., van Baren M.J., Schaap O., Breedveld G.J., Krieger E., Dekker M.C., Squitieri F., Ibanez P., Joosse M., van Dongen J.W., Vanacore N., van Swieten J.C., Brice A., Meco G., van Duijn C.M., Oostra B.A., Heutink P. Mutations in the DJ-1 gene associated with autosomal recessive early-onset Parkinsonism. Science 2003, 299:256-259.
10. Braak H., Del Tredici K. Neuroanatomy and pathology of sporadic Parkinson's disease. Adv Anat Embryol Cell Biol 2009, 201:1-119.
11. Braak H., Del Tredici K., Rub U., de Vos R.A., Jansen Steur E.N., Braak E. Staging of brain pathology related to sporadic Parkinson's disease. Neurobiol Aging 2003, 24:197-211.
12. Brochard V., Combadiere B., Prigent A., Laouar Y., Perrin A., Beray-Berthat V., Bonduelle O., Alvarez-Fischer D., Callebert J., Launay J.M., Duyckaerts C., Flavell R.A., Hirsch E.C., Hunot S. Infiltration of CD4+ lymphocytes into the brain contributes to neurodegeneration in a mouse model of Parkinson disease. J Clin Invest 2009, 119:182-192.
13. Brockmann K., Berg D. The significance of GBA for Parkinson's disease. J Inherit Metab Dis 2014, 37:643-648.
14. Brodacki B., Staszewski J., Toczylowska B., Kozlowska E., Drela N., Chalimoniuk M., Stepien A. Serum interleukin (IL-2, IL-10, IL-6, IL-4), TNFalpha, and INFgamma concentrations are elevated in patients with atypical and idiopathic parkinsonism. Neurosci Lett 2008, 441:158-162.
15. Capuron L., Schroecksnadel S., Feart C., Aubert A., Higueret D., Barberger-Gateau P., Laye S., Fuchs D. Chronic low-grade inflammation in elderly persons is associated with altered tryptophan and tyrosine metabolism: role in neuropsychiatric symptoms. Biol Psychiatry 2011, 70:175-182.
16. Cardoso C.C., Pereira A.C., de Sales Marques.C., Moraes M.O. Leprosy susceptibility: genetic variations regulate innate and adaptive immunity, and disease outcome. Future Microbiol 2011, 6:533-549.
17. Chavarria C., Souza J.M. Oxidation and nitration of alpha-synuclein and their implications in neurodegenerative diseases. Arch Biochem Biophys 2013, 533:25-32.
18. Chesselet M.F., Richter F., Zhu C., Magen I., Watson M.B., Subramaniam S.R. A progressive mouse model of Parkinson's disease: the Thy1-aSyn ("Line 61") mice. Neurotherapeutics 2012, 9:297-314.
19. Chopra R., Kalaiarasan P., Ali S., Srivastava A.K., Aggarwal S., Garg V.K., Bhattacharya S.N., Bamezai R.N. PARK2 and proinflammatory/anti-inflammatory cytokine gene interactions contribute to the susceptibility to leprosy: a case-control study of North Indian population. BMJ Open 2014, 4:e004239.
20. Chung J.Y., Park H.R., Lee S.J., Lee S.H., Kim J.S., Jung Y.S., Hwang S.H., Ha N.C., Seol W.G., Lee J., Park B.J. Elevated TRAF2/6 expression in Parkinson's disease is caused by the loss of Parkin E3 ligase activity. Lab Invest 2013, 93:663-676.
21. Cicchetti F., Brownell A.L., Williams K., Chen Y.I., Livni E., Isacson O. Neuroinflammation of the nigrostriatal pathway during progressive 6-OHDA dopamine degeneration in rats monitored by immunohistochemistry and PET imaging. Eur J Neurosci 2002, 15:991-998.
22. Clark I.E., Dodson M.W., Jiang C., Cao J.H., Huh J.R., Seol J.H., Yoo S.J., Hay B.A., Guo M. Drosophila pink1 is required for mitochondrial function and interacts genetically with parkin. Nature 2006, 441:1162-1166.
23. Codolo G., Plotegher N., Pozzobon T., Brucale M., Tessari I., Bubacco L., de Bernard M. Triggering of inflammasome by aggregated alpha-synuclein, an inflammatory response in synucleinopathies. PloS One 2013, 8:e55375.
24. Collins L.M., Toulouse A., Connor T.J., Nolan Y.M. Contributions of central and systemic inflammation to the pathophysiology of Parkinson's disease. Neuropharmacology 2012, 62:2154-2168.
25. Comoglu S.S., Guven H., Acar M., Ozturk G., Kocer B. Tear levels of tumor necrosis factor-alpha in patients with Parkinson's disease. Neurosci Lett 2013, 553:63-67.
26. Cookson M.R. Parkinsonism due to mutations in PINK1, parkin, and DJ-1 and oxidative stress and mitochondrial pathways. Cold Spring Harbor Perspect Med 2012, 2:a009415.
27. Cornejo Castro E.M., Waak J., Weber S.S., Fiesel F.C., Oberhettinger P., Schutz M., Autenrieth I.B., Springer W., Kahle P.J. Parkinson's disease-associated DJ-1 modulates innate immunity signaling in Caenorhabditis elegans. J Neural Transm 2010, 117:599-604.
28. Couch Y., Alvarez-Erviti L., Sibson N.R., Wood M.J., Anthony D.C. The acute inflammatory response to intranigral alpha-synuclein differs significantly from intranigral lipopolysaccharide and is exacerbated by peripheral inflammation. J Neuroinflamm 2011, 8:166.
29. Dawson T.M., Dawson V.L. The role of parkin in familial and sporadic Parkinson's disease. Mov Disord 2010, 25(suppl. 1):S32-39.
30. Deng X., Choi H.G., Buhrlage S.J., Gray N.S. Leucine-rich repeat kinase 2 inhibitors: a patent review (2006-2011). Expert Opin Ther Patents 2012, 22:1415-1426.
31. Dobbs R.J., Charlett A., Purkiss A.G., Dobbs S.M., Weller C., Peterson D.W. Association of circulating TNF-alpha and IL-6 with ageing and parkinsonism. Acta Neurol Scand 1999, 100:34-41.
32. Dupre-Crochet S., Erard M., Nubetae O. ROS production in phagocytes: why, when, and where?. J Leuko Biol 2013, 94:657-670.
33. Dzamko N., Chua G., Ranola M., Rowe D.B., Halliday G.M. Measurement of LRRK2 and Ser910/935 phosphorylated LRRK2 in peripheral blood mononuclear cells from idiopathic Parkinson's disease patients. J Parkinson's Dis 2013, 3:145-152.
34. Dzamko N., Deak M., Hentati F., Reith A.D., Prescott A.R., Alessi D.R., Nichols R.J. Inhibition of LRRK2 kinase activity leads to dephosphorylation of Ser(910)/Ser(935), disruption of 14-3-3 binding and altered cytoplasmic localization. Biochem J 2010, 430:405-413.
35. Dzamko N., Halliday G.M. An emerging role for LRRK2 in the immune system. Biochem Soc Trans 2012, 40:1134-1139.
36. Dzamko N., Inesta-Vaquera F., Zhang J., Xie C., Cai H., Arthur S., Tan L., Choi H., Gray N., Cohen P., Pedrioli P., Clark K., Alessi D.R. The IkappaB kinase family phosphorylates the Parkinson's disease kinase LRRK2 at Ser935 and Ser910 during Toll-like receptor signaling. PloS One 2012, 7:e39132.
37. Ellis G.I., Zhi L., Akundi R., Bueler H., Marti F. Mitochondrial and cytosolic roles of PINK1 shape induced regulatory T-cell development and function. Eur. J Immunol 2013, 43:3355-3360.
38. Enquist I.B., Lo Bianco C., Ooka A., Nilsson E., Mansson J.E., Ehinger M., Richter J., Brady R.O., Kirik D., Karlsson S. Murine models of acute neuronopathic Gaucher disease. Proc Natl Acad Sci USA 2007, 104:17483-17488.
39. Fang F., Wirdefeldt K., Jacks A., Kamel F., Ye W., Chen H. CNS infections, sepsis and risk of Parkinson's disease. Int J Epidemiol 2012.
40. Farfel-Becker T., Vitner E.B., Pressey S.N., Eilam R., Cooper J.D., Futerman A.H. Spatial and temporal correlation between neuron loss and neuroinflammation in a mouse model of neuronopathic Gaucher disease. Hum Mol Genet 2011, 20:1375-1386.
41. Fellner L., Irschick R., Schanda K., Reindl M., Klimaschewski L., Poewe W., Wenning G.K., Stefanova N. Toll-like receptor 4 is required for alpha-synuclein dependent activation of microglia and astroglia. Glia 2013, 61:349-360.
42. Fiszer U., Mix E., Fredrikson S., Kostulas V., Olsson T., Link H. Gamma delta+ T cells are increased in patients with Parkinson's disease. J Neurol Sci 1994, 121:39-45.
43. Forsyth C.B., Shannon K.M., Kordower J.H., Voigt R.M., Shaikh M., Jaglin J.A., Estes J.D., Dodiya H.B., Keshavarzian A. Increased intestinal permeability correlates with sigmoid mucosa alpha-synuclein staining and endotoxin exposure markers in early Parkinson's disease. PloS One 2011, 6:e28032.
44. Frank-Cannon T.C., Tran T., Ruhn K.A., Martinez T.N., Hong J., Marvin M., Hartley M., Trevino I., O'Brien D.E., Casey B., Goldberg M.S., Tansey M.G. Parkin deficiency increases vulnerability to inflammation-related nigral degeneration. J Neurosci 2008, 28:10825-10834.
45. Fujiwara H., Hasegawa M., Dohmae N., Kawashima A., Masliah E., Goldberg M.S., Shen J., Takio K., Iwatsubo T. Alpha-synuclein is phosphorylated in synucleinopathy lesions. Nat Cell Biol 2002, 4:160-164.
46. Gao H.M., Kotzbauer P.T., Uryu K., Leight S., Trojanowski J.Q., Lee V.M. Neuroinflammation and oxidation/nitration of alpha-synuclein linked to dopaminergic neurodegeneration. J Neurosci 2008, 28:7687-7698.
47. Gardet A., Benita Y., Li C., Sands B.E., Ballester I., Stevens C., Korzenik J.R., Rioux J.D., Daly M.J., Xavier R.J., Podolsky D.K. LRRK2 is involved in the IFN-gamma response and host response to pathogens. J Immunol 2010, 185:5577-5585.
48. Gegg M.E., Burke D., Heales S.J., Cooper J.M., Hardy J., Wood N.W., Schapira A.H. Glucocerebrosidase deficiency in substantia nigra of parkinson disease brains. Ann Neurol 2012, 72:455-463.
49. Giasson B.I., Duda J.E., Murray I.V., Chen Q., Souza J.M., Hurtig H.I., Ischiropoulos H., Trojanowski J.Q., Lee V.M. Oxidative damage linked to neurodegeneration by selective alpha-synuclein nitration in synucleinopathy lesions. Science 2000, 290:985-989.
50. Gillardon F., Schmid R., Draheim H. Parkinson's disease-linked leucine-rich repeat kinase 2(R1441G) mutation increases proinflammatory cytokine release from activated primary microglial cells and resultant neurotoxicity. Neuroscience 2012, 208:41-48.
51. Goker-Alpan O., Schiffmann R., LaMarca M.E., Nussbaum R.L., McInerney-Leo A., Sidransky E. Parkinsonism among Gaucher disease carriers. J Med Genet 2004, 41:937-940.
52. Greene J.C., Whitworth A.J., Andrews L.A., Parker T.J., Pallanck L.J. Genetic and genomic studies of Drosophila parkin mutants implicate oxidative stress and innate immune responses in pathogenesis. Hum Mol Genet 2005, 14:799-811.
53. Hakimi M., Selvanantham T., Swinton E., Padmore R.F., Tong Y., Kabbach G., Venderova K., Girardin S.E., Bulman D.E., Scherzer C.R., LaVoie M.J., Gris D., Park D.S., Angel J.B., Shen J., Philpott D.J., Schlossmacher M.G. Parkinson's disease-linked LRRK2 is expressed in circulating and tissue immune cells and upregulated following recognition of microbial structures. J Neural Transm 2011, 118:795-808.
54. Halperin A., Elstein D., Zimran A. Increased incidence of Parkinson disease among relatives of patients with Gaucher disease. Blood Cells Mol Dis 2006, 36:426-428.
55. Hamza T.H., Zabetian C.P., Tenesa A., Laederach A., Montimurro J., Yearout D., Kay D.M., Doheny K.F., Paschall J., Pugh E., Kusel V.I., Collura R., Roberts J., Griffith A., Samii A., Scott W.K., Nutt J., Factor S.A., Payami H. Common genetic variation in the HLA region is associated with late-onset sporadic Parkinson's disease. Nat Genet 2010, 42:781-785.
56. Hawkes C.H., Del Tredici K., Braak H. Parkinson's disease: a dual-hit hypothesis. Neuropathol Appl Neurobiol 2007, 33:599-614.
57. Healy D.G., Falchi M., O'Sullivan S.S., Bonifati V., Durr A., Bressman S., Brice A., Aasly J., Zabetian C.P., Goldwurm S., Ferreira J.J., Tolosa E., Kay D.M., Klein C., Williams D.R., Marras C., Lang A.E., Wszolek Z.K., Berciano J., Schapira A.H., Lynch T., Bhatia K.P., Gasser T., Lees A.J., Wood N.W. Phenotype, genotype, and worldwide genetic penetrance of LRRK2-associated Parkinson's disease: a case-control study. Lancet Neurol 2008, 7:583-590.
58. Heeman B., Van den Haute C., Aelvoet S.A., Valsecchi F., Rodenburg R.J., Reumers V., Debyser Z., Callewaert G., Koopman W.J., Willems P.H., Baekelandt V. Depletion of PINK1 affects mitochondrial metabolism, calcium homeostasis and energy maintenance. J Cell Sci 2011, 124:1115-1125.
59. Henn I.H., Bouman L., Schlehe J.S., Schlierf A., Schramm J.E., Wegener E., Nakaso K., Culmsee C., Berninger B., Krappmann D., Tatzelt J., Winklhofer K.F. Parkin mediates neuroprotection through activation of IkappaB kinase/nuclear factor-kappaB signaling. J Neurosci 2007, 27:1868-1878.
60. Hirsch E.C., Vyas S., Hunot S. Neuroinflammation in Parkinson's disease. Parkinsonism Relat Disord 2012, 18(suppl. 1):S210-212.
61. Holmans P., Moskvina V., Jones L., Sharma M., Vedernikov A., Buchel F., Saad M., Bras J.M., Bettella F., Nicolaou N., Simon-Sanchez J., Mittag F., Gibbs J.R., Schulte C., Durr A., Guerreiro R., Hernandez D., Brice A., Stefansson H., Majamaa K., Gasser T., Heutink P., Wood N.W., Martinez M., Singleton A.B., Nalls M.A., Hardy J., Morris H.R., Williams N.M. A pathway-based analysis provides additional support for an immune-related genetic susceptibility to Parkinson's disease. Hum Mol Genet 2013, 22:1039-1049.
62. Howell W.M. HLA and disease: guilt by association. Int J Immunogenet 2014, 41:1-12.
63. Jaleel M., Nichols R.J., Deak M., Campbell D.G., Gillardon F., Knebel A., Alessi D.R. LRRK2 phosphorylates moesin at threonine-558: characterization of how Parkinson's disease mutants affect kinase activity. Biochem J 2007, 405:307-317.
64. Jang H., Boltz D., Sturm-Ramirez K., Shepherd K.R., Jiao Y., Webster R., Smeyne R.J. Highly pathogenic H5N1 influenza virus can enter the central nervous system and induce neuroinflammation and neurodegeneration. Proc Natl Acad Sci USA 2009, 106:14063-14068.
65. Jang H., Boltz D.A., Webster R.G., Smeyne R.J. Viral parkinsonism. Biochim Biophys Acta 2009, 1792:714-721.
66. Jeffers M., McDonald W.F., Chillakuru R.A., Yang M., Nakase H., Deegler L.L., Sylander E.D., Rittman B., Bendele A., Sartor R.B., Lichenstein H.S. A novel human fibroblast growth factor treats experimental intestinal inflammation. Gastroenterology 2002, 123:1151-1162.
67. Jeon T.I., Osborne T.F. SREBPs: metabolic integrators in physiology and metabolism. Trends Endocrinol Metab 2012, 23:65-72.
68. Kahle P.J., Waak J., Gasser T. DJ-1 and prevention of oxidative stress in Parkinson's disease and other age-related disorders. Free Radic Biol Med 2009, 47:1354-1361.
69. Kawajiri S., Saiki S., Sato S., Hattori N. Genetic mutations and functions of PINK1. Trends Pharmacol Sci 2011, 32:573-580.
70. Kethiri R.R., Bakthavatchalam R. Leucine-rich repeat kinase 2 inhibitors: a review of recent patents (2011-2013). Expert Opin Ther Patents 2014, 24:745-757.
71. Kim B., Yang M.S., Choi D., Kim J.H., Kim H.S., Seol W., Choi S., Jou I., Kim E.Y., Joe E.H. Impaired inflammatory responses in murine LRRK2-knockdown brain microglia. PloS One 2012, 7:e34693.
72. Kim C., Ho D.H., Suk J.E., You S., Michael S., Kang J., Joong Lee S., Masliah E., Hwang D., Lee H.J., Lee S.J. Neuron-released oligomeric alpha-synuclein is an endogenous agonist of TLR2 for paracrine activation of microglia. Nat Commun 2013, 4:1562.
73. Kim H.Y., Choi B.S., Kim S., Roh T.Y., Park J., Yoon C.H. NUCKS1, a novel Tat coactivator, plays a crucial role in HIV-1 replication by increasing Tat-mediated viral transcription on the HIV-1 LTR promoter. Retrovirology 2014, 11:67.
74. Kim J., Byun J.W., Choi I., Kim B., Jeong H.K., Jou I., Joe E. PINK1 deficiency enhances inflammatory cytokine release from acutely prepared brain slices. Exp Neurobiol 2013, 22:38-44.
75. Kitada T., Asakawa S., Hattori N., Matsumine H., Yamamura Y., Minoshima S., Yokochi M., Mizuno Y., Shimizu N. Mutations in the parkin gene cause autosomal recessive juvenile Parkinsonism. Nature 1998, 392:605-608.
76. Kondapalli C., Kazlauskaite A., Zhang N., Woodroof H.I., Campbell D.G., Gourlay R., Burchell L., Walden H., Macartney T.J., Deak M., Knebel A., Alessi D.R., Muqit M.M. PINK1 is activated by mitochondrial membrane potential depolarization and stimulates Parkin E3 ligase activity by phosphorylating Serine 65. Open Biol 2012, 2:120080.
77. Koziorowski D., Tomasiuk R., Szlufik S., Friedman A. Inflammatory cytokines and NT-proCNP in Parkinson's disease patients. Cytokine 2012, 60:762-766.
78. Kurkowska-Jastrzebska I., Wronska A., Kohutnicka M., Czlonkowski A., Czlonkowska A. The inflammatory reaction following 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine intoxication in mouse. Exp Neurol 1999, 156:50-61.
79. Lee H.J., Chung K.C. PINK1 positively regulates IL-1beta-mediated signaling through Tollip and IRAK1 modulation. J Neuroinflamm 2012, 9:271.
80. Lee H.J., Jang S.H., Kim H., Yoon J.H., Chung K.C. PINK1 stimulates interleukin-1beta-mediated inflammatory signaling via the positive regulation of TRAF6 and TAK1. Cell Mol Life Sci 2012, 69:3301-3315.
81. Lindqvist D., Kaufman E., Brundin L., Hall S., Surova Y., Hansson O. Non-motor symptoms in patients with Parkinson's disease - correlations with inflammatory cytokines in serum. PloS One 2012, 7:e47387.
82. Liu Z., Lee J., Krummey S., Lu W., Cai H., Lenardo M.J. The kinase LRRK2 is a regulator of the transcription factor NFAT that modulates the severity of inflammatory bowel disease. Nat Immunol 2011, 12:1063-1070.
83. Lopez de Maturana R., Aguila J.C., Sousa A., Vazquez N., Del Rio P., Aiastui A., Gorostidi A., Lopez de Munain A., Sanchez-Pernaute R. Leucine-rich repeat kinase 2 modulates cyclooxygenase 2 and the inflammatory response in idiopathic and genetic Parkinson's disease. Neurobiol Aging 2014, 35:1116-1124.
84. Lopez-Armada M.J., Riveiro-Naveira R.R., Vaamonde-Garcia C., Valcarcel-Ares M.N. Mitochondrial dysfunction and the inflammatory response. Mitochondrion 2013, 13:106-118.
85. Luerman G.C., Nguyen C., Samaroo H., Loos P., Xi H., Hurtado-Lorenzo A., Needle E., Stephen Noell G., Galatsis P., Dunlop J., Geoghegan K.F., Hirst W.D. Phosphoproteomic evaluation of pharmacological inhibition of leucine-rich repeat kinase 2 reveals significant off-target effects of LRRK-2-IN-1. J Neurochem 2014, 128:561-576.
86. Manzanillo P.S., Ayres J.S., Watson R.O., Collins A.C., Souza G., Rae C.S., Schneider D.S., Nakamura K., Shiloh M.U., Cox J.S. The ubiquitin ligase parkin mediates resistance to intracellular pathogens. Nature 2013, 501:512-516.
87. Marcinek P., Jha A.N., Shinde V., Sundaramoorthy A., Rajkumar R., Suryadevara N.C., Neela S.K., van Tong H., Balachander V., Valluri V.L., Thangaraj K., Velavan T.P. LRRK2 and RIPK2 variants in the NOD 2-mediated signaling pathway are associated with susceptibility to Mycobacterium leprae in Indian populations. PloS One 2013, 8:e73103.
88. Matsuda N., Sato S., Shiba K., Okatsu K., Saisho K., Gautier C.A., Sou Y.S., Saiki S., Kawajiri S., Sato F., Kimura M., Komatsu M., Hattori N., Tanaka K. PINK1 stabilized by mitochondrial depolarization recruits Parkin to damaged mitochondria and activates latent Parkin for mitophagy. J Cell Biol 2010, 189:211-221.
89. McGeer P.L., Itagaki S., Boyes B.E., McGeer E.G. Reactive microglia are positive for HLA-DR in the substantia nigra of Parkinson's and Alzheimer's disease brains. Neurology 1988, 38:1285-1291.
90. McGeer P.L., McGeer E.G. Inflammation and neurodegeneration in Parkinson's disease. Parkinsonism Relat Disord 2004, 10(suppl. 1):S3-7.
91. Meiser J., Weindl D., Hiller K. Complexity of dopamine metabolism. Cell Commun Signal 2013, 11:34.
92. Menza M., Dobkin R.D., Marin H., Mark M.H., Gara M., Bienfait K., Dicke A., Kusnekov A. The role of inflammatory cytokines in cognition and other non-motor symptoms of Parkinson's disease. Psychosomatics 2010, 51:474-479.
93. Mira M.T., Alcais A., Nguyen V.T., Moraes M.O., Di Flumeri C., Vu H.T., Mai C.P., Nguyen T.H., Nguyen N.B., Pham X.K., Sarno E.N., Alter A., Montpetit A., Moraes M.E., Moraes J.R., Dore C., Gallant C.J., Lepage P., Verner A., Van De Vosse E., Hudson T.J., Abel L., Schurr E. Susceptibility to leprosy is associated with PARK2 and PACRG. Nature 2004, 427:636-640.
94. Mitsumoto A., Nakagawa Y. DJ-1 is an indicator for endogenous reactive oxygen species elicited by endotoxin. Free Radic Res 2001, 35:885-893.
95. Mizukami H., Mi Y., Wada R., Kono M., Yamashita T., Liu Y., Werth N., Sandhoff R., Sandhoff K., Proia R.L. Systemic inflammation in glucocerebrosidase-deficient mice with minimal glucosylceramide storage. J Clin Invest 2002, 109:1215-1221.
96. Moehle M.S., Webber P.J., Tse T., Sukar N., Standaert D.G., DeSilva T.M., Cowell R.M., West A.B. LRRK2 inhibition attenuates microglial inflammatory responses. J Neurosci 2012, 32:1602-1611.
97. Mogi M., Harada M., Narabayashi H., Inagaki H., Minami M., Nagatsu T. Interleukin (IL)-1 beta, IL-2, IL-4, IL-6 and transforming growth factor-alpha levels are elevated in ventricular cerebrospinal fluid in juvenile parkinsonism and Parkinson's disease. Neurosci Lett 1996, 211:13-16.
98. Mogi M., Harada M., Riederer P., Narabayashi H., Fujita K., Nagatsu T. Tumor necrosis factor-alpha (TNF-alpha) increases both in the brain and in the cerebrospinal fluid from parkinsonian patients. Neurosci Lett 1994, 165:208-210.
99. Mortiboys H., Thomas K.J., Koopman W.J., Klaffke S., Abou-Sleiman P., Olpin S., Wood N.W., Willems P.H., Smeitink J.A., Cookson M.R., Bandmann O. Mitochondrial function and morphology are impaired in parkin-mutant fibroblasts. Ann Neurol 2008, 64:555-565.
100. Mount M.P., Lira A., Grimes D., Smith P.D., Faucher S., Slack R., Anisman H., Hayley S., Park D.S. Involvement of interferon-gamma in microglial-mediated loss of dopaminergic neurons. J Neurosci 2007, 27:3328-3337.
101. Muller T., Blum-Degen D., Przuntek H., Kuhn W. Interleukin-6 levels in cerebrospinal fluid inversely correlate to severity of Parkinson's disease. Acta Neurol Scand 1998, 98:142-144.
102. Muller-Rischart A.K., Pilsl A., Beaudette P., Patra M., Hadian K., Funke M., Peis R., Deinlein A., Schweimer C., Kuhn P.H., Lichtenthaler S.F., Motori E., Hrelia S., Wurst W., Trumbach D., Langer T., Krappmann D., Dittmar G., Tatzelt J., Winklhofer K.F. The E3 ligase parkin maintains mitochondrial integrity by increasing linear ubiquitination of NEMO. Mol Cell 2013, 49:908-921.
103. Murphy K.E., Gysbers A.M., Abbott S.K., Tayebi N., Kim W.S., Sidransky E., Cooper A., Garner B., Halliday G.M. Reduced glucocerebrosidase is associated with increased alpha-synuclein in sporadic Parkinson's disease. Brain 2014, 137:834-848.
104. Mutez E., Larvor L., Lepretre F., Mouroux V., Hamalek D., Kerckaert J.P., Perez-Tur J., Waucquier N., Vanbesien-Mailliot C., Duflot A., Devos D., Defebvre L., Kreisler A., Frigard B., Destee A., Chartier-Harlin M.C. Transcriptional profile of Parkinson blood mononuclear cells with LRRK2 mutation. Neurobiol Aging 2011, 32:1839-1848.
105. Naik E., Dixit V.M. Mitochondrial reactive oxygen species drive proinflammatory cytokine production. J Exp Med 2011, 208:417-420.
106. Nalls M.A., Pankratz N., Lill C.M., Do C.B., Hernandez D.G., Saad M., DeStefano A.L., Kara E., Bras J., Sharma M., Schulte C., Keller M.F., Arepalli S., Letson C., Edsall C., Stefansson H., Liu X., Pliner H., Lee J.H., Cheng R., Ikram M.A., Ioannidis J.P., Hadjigeorgiou G.M., Bis J.C., Martinez M., Perlmutter J.S., Goate A., Marder K., Fiske B., Sutherland M., Xiromerisiou G., Myers R.H., Clark L.N., Stefansson K., Hardy J.A., Heutink P., Chen H., Wood N.W., Houlden H., Payami H., Brice A., Scott W.K., Gasser T., Bertram L., Eriksson N., Foroud T., Singleton A.B. Large-scale meta-analysis of genome-wide association data identifies six new risk loci for Parkinson's disease. Nat Genet 2014, 46:989-993.
107. Nalls M.A., Saad M., Noyce A.J., Keller M.F., Schrag A., Bestwick J.P., Traynor B.J., Gibbs J.R., Hernandez D.G., Cookson M.R., Morris H.R., Williams N., Gasser T., Heutink P., Wood N., Hardy J., Martinez M., Singleton A.B. Genetic comorbidities in Parkinson's disease. Hum Mol Genet 2014, 23:831-841.
108. Narendra D., Tanaka A., Suen D.F., Youle R.J. Parkin is recruited selectively to impaired mitochondria and promotes their autophagy. J Cell Biol 2008, 183:795-803.
109. Narendra D.P., Jin S.M., Tanaka A., Suen D.F., Gautier C.A., Shen J., Cookson M.R., Youle R.J. PINK1 is selectively stabilized on impaired mitochondria to activate Parkin. PLoS Biol 2010, 8:e1000298.
110. Narendra D.P., Youle R.J. Targeting mitochondrial dysfunction: role for PINK1 and Parkin in mitochondrial quality control. Antioxid Redox Signal 2011, 14:1929-1938.
111. Nasser A., Bjerrum O.J., Heegaard A.M., Moller A.T., Larsen M., Dalboge L.S., Dupont E., Jensen T.S., Moller L.B. Impaired behavioural pain responses in hph-1 mice with inherited deficiency in GTP cyclohydrolase 1 in models of inflammatory pain. Mol Pain 2013, 9:5.
112. Nguyen T.A., Frank-Cannon T., Martinez T.N., Ruhn K.A., Marvin M., Casey B., Trevino I., Hong J.J., Goldberg M.S., Tansey M.G. Analysis of inflammation-related nigral degeneration and locomotor function in DJ-1(-/-) mice. J Neuroinflamm 2013, 10:50.
113. Nichols R.J., Dzamko N., Morrice N.A., Campbell D.G., Deak M., Ordureau A., Macartney T., Tong Y., Shen J., Prescott A.R., Alessi D.R. 14-3-3 binding to LRRK2 is disrupted by multiple Parkinson's disease-associated mutations and regulates cytoplasmic localization. Biochem J 2010, 430:393-404.
114. Nicoletti A., Fagone P., Donzuso G., Mangano K., Dibilio V., Caponnetto S., Bendtzen K., Zappia M., Nicoletti F. Parkinson's disease is associated with increased serum levels of macrophage migration inhibitory factor. Cytokine 2011, 55:165-167.
115. Niehaus I., Lange J.H. Endotoxin: is it an environmental factor in the cause of Parkinson's disease?. Occup Environ Med 2003, 60:378.
116. Ogata A., Tashiro K., Nukuzuma S., Nagashima K., Hall W.W. A rat model of Parkinson's disease induced by Japanese encephalitis virus. J Neurovirol 1997, 3:141-147.
117. Okada Y., Hirota T., Kamatani Y., Takahashi A., Ohmiya H., Kumasaka N., Higasa K., Yamaguchi-Kabata Y., Hosono N., Nalls M.A., Chen M.H., van Rooij F.J., Smith A.V., Tanaka T., Couper D.J., Zakai N.A., Ferrucci L., Longo D.L., Hernandez D.G., Witteman J.C., Harris T.B., O'Donnell C.J., Ganesh S.K., Matsuda K., Tsunoda T., Tanaka T., Kubo M., Nakamura Y., Tamari M., Yamamoto K., Kamatani N. Identification of nine novel loci associated with white blood cell subtypes in a Japanese population. PLoS Genet 2011, 7:e1002067.
118. Olanow C.W., Brundin P. Parkinson's disease and alpha synuclein: is Parkinson's disease a prion-like disorder?. Mov Disord 2013, 28:31-40.
119. Orr C.F., Rowe D.B., Halliday G.M. An inflammatory review of Parkinson's disease. Prog Neurobiol 2002, 68:325-340.
120. Paisan-Ruiz C., Jain S., Evans E.W., Gilks W.P., Simon J., van der Brug M., Lopez de Munain A., Aparicio S., Gil A.M., Khan N., Johnson J., Martinez J.R., Nicholl D., Carrera I.M., Pena A.S., de Silva R., Lees A., Marti-Masso J.F., Perez-Tur J., Wood N.W., Singleton A.B. Cloning of the gene containing mutations that cause PARK8-linked Parkinson's disease. Neuron 2004, 44:595-600.
121. Palacino J.J., Sagi D., Goldberg M.S., Krauss S., Motz C., Wacker M., Klose J., Shen J. Mitochondrial dysfunction and oxidative damage in parkin-deficient mice. J Biol Chem 2004, 279:18614-18622.
122. Park J., Lee S.B., Lee S., Kim Y., Song S., Kim S., Bae E., Kim J., Shong M., Kim J.M., Chung J. Mitochondrial dysfunction in Drosophila PINK1 mutants is complemented by parkin. Nature 2006, 441:1157-1161.
123. Pelletier M., Lepow T.S., Billingham L.K., Murphy M.P., Siegel R.M. New tricks from an old dog: mitochondrial redox signaling in cellular inflammation. Semin Immunol 2012, 24:384-392.
124. Perry V.H. The influence of systemic inflammation on inflammation in the brain: implications for chronic neurodegenerative disease. Brain Behav Immun 2004, 18:407-413.
125. Piccinini A.M., Midwood K.S. DAMPening inflammation by modulating TLR signalling. Mediat Inflamm 2010.
126. Plato A., Willment J.A., Brown G.D. C-type lectin-like receptors of the dectin-1 cluster: ligands and signaling pathways. Int Rev Immunol 2013, 32:134-156.
127. Polymeropoulos M.H., Lavedan C., Leroy E., Ide S.E., Dehejia A., Dutra A., Pike B., Root H., Rubenstein J., Boyer R., Stenroos E.S., Chandrasekharappa S., Athanassiadou A., Papapetropoulos T., Johnson W.G., Lazzarini A.M., Duvoisin R.C., Di Iorio G., Golbe L.I., Nussbaum R.L. Mutation in the alpha-synuclein gene identified in families with Parkinson's disease. Science 1997, 276:2045-2047.
128. Puschmann A., Verbeeck C., Heckman M.G., Soto-Ortolaza A.I., Lynch T., Jasinska-Myga B., Opala G., Krygowska-Wajs A., Barcikowska M., Uitti R.J., Wszolek Z.K., Ross O.A. Human leukocyte antigen variation and Parkinson's disease. Parkinsonism Relat Disord 2011, 17:376-378.
129. Qin L., Wu X., Block M.L., Liu Y., Breese G.R., Hong J.S., Knapp D.J., Crews F.T. Systemic LPS causes chronic neuroinflammation and progressive neurodegeneration. Glia 2007, 55:453-462.
130. Quarona V., Zaccarello G., Chillemi A., Brunetti E., Singh V.K., Ferrero E., Funaro A., Horenstein A.L., Malavasi F. CD38 and CD157: a long journey from activation markers to multifunctional molecules. Cytometry Part B 2013, 84:207-217.
131. Raj T., Rothamel K., Mostafavi S., Ye C., Lee M.N., Replogle J.M., Feng T., Lee M., Asinovski N., Frohlich I., Imboywa S., Von Korff A., Okada Y., Patsopoulos N.A., Davis S., McCabe C., Paik H.I., Srivastava G.P., Raychaudhuri S., Hafler D.A., Koller D., Regev A., Hacohen N., Mathis D., Benoist C., Stranger B.E., De Jager P.L. Polarization of the effects of autoimmune and neurodegenerative risk alleles in leukocytes. Science 2014, 344:519-523.
132. Reale M., Iarlori C., Thomas A., Gambi D., Perfetti B., Di Nicola M., Onofrj M. Peripheral cytokines profile in Parkinson's disease. Brain Behavior Immun 2009, 23:55-63.
133. Rentzos M., Nikolaou C., Andreadou E., Paraskevas G.P., Rombos A., Zoga M., Tsoutsou A., Boufidou F., Kapaki E., Vassilopoulos D. Circulating interleukin-15 and RANTES chemokine in Parkinson's disease. Acta Neurol Scand 2007, 116:374-379.
134. Rentzos M., Nikolaou C., Andreadou E., Paraskevas G.P., Rombos A., Zoga M., Tsoutsou A., Boufidou F., Kapaki E., Vassilopoulos D. Circulating interleukin-10 and interleukin-12 in Parkinson's disease. Acta Neurol Scand 2009, 119:332-337.
135. Reynolds A.D., Stone D.K., Hutter J.A., Benner E.J., Mosley R.L., Gendelman H.E. Regulatory T cells attenuate Th17 cell-mediated nigrostriatal dopaminergic neurodegeneration in a model of Parkinson's disease. J Immunol 2010, 184:2261-2271.
136. Roodveldt C., Labrador-Garrido A., Gonzalez-Rey E., Lachaud C.C., Guilliams T., Fernandez-Montesinos R., Benitez-Rondan A., Robledo G., Hmadcha A., Delgado M., Dobson C.M., Pozo D. Preconditioning of microglia by alpha-synuclein strongly affects the response induced by toll-like receptor (TLR) stimulation. PloS One 2013, 8:e79160.
137. Rosenbloom B.E., Weinreb N.J. Gaucher disease: a comprehensive review. Crit Rev Oncogen 2013, 18:163-175.
138. Rudenko I.N., Chia R., Cookson M.R. Is inhibition of kinase activity the only therapeutic strategy for LRRK2-associated Parkinson's disease?. BMC Med 2012, 10:20.
139. Russo I., Bubacco L., Greggio E. LRRK2 and neuroinflammation: partners in crime in Parkinson's disease?. J Neuroinflamm 2014, 11:52.
140. Satake W., Nakabayashi Y., Mizuta I., Hirota Y., Ito C., Kubo M., Kawaguchi T., Tsunoda T., Watanabe M., Takeda A., Tomiyama H., Nakashima K., Hasegawa K., Obata F., Yoshikawa T., Kawakami H., Sakoda S., Yamamoto M., Hattori N., Murata M., Nakamura Y., Toda T. Genome-wide association study identifies common variants at four loci as genetic risk factors for Parkinson's disease. Nat Genet 2009, 41:1303-1307.
141. Saunders J.A., Estes K.A., Kosloski L.M., Allen H.E., Dempsey K.M., Torres-Russotto D.R., Meza J.L., Santamaria P.M., Bertoni J.M., Murman D.L., Ali H.H., Standaert D.G., Mosley R.L., Gendelman H.E. CD4+ regulatory and effector/memory T cell subsets profile motor dysfunction in Parkinson's disease. J Neuroimmune Pharmacol 2012, 7:927-938.
142. Scalzo P., Kummer A., Cardoso F., Teixeira A.L. Increased serum levels of soluble tumor necrosis factor-alpha receptor-1 in patients with Parkinson's disease. J Neuroimmunol 2009, 216:122-125.
143. Scalzo P., Kummer A., Cardoso F., Teixeira A.L. Serum levels of interleukin-6 are elevated in patients with Parkinson's disease and correlate with physical performance. Neurosci Lett 2010, 468:56-58.
144. Scarffe L.A., Stevens D.A., Dawson V.L., Dawson T.M. Parkin and PINK1: much more than mitophagy. Trends Neurosci 2014, 37:315-324.
145. Schapansky J., Nardozzi J.D., Felizia F., Lavoie M.J. Membrane recruitment of endogenous LRRK2 precedes its potent regulation of autophagy. Hum Mol Genet 2014.
146. Schildknecht S., Gerding H.R., Karreman C., Drescher M., Lashuel H.A., Outeiro T.F., Di Monte D.A., Leist M. Oxidative and nitrative alpha-synuclein modifications and proteostatic stress: implications for disease mechanisms and interventions in synucleinopathies. J Neurochem 2013, 125:491-511.
147. Schulte C., Gasser T. Genetic basis of Parkinson's disease: inheritance, penetrance, and expression. Appl Clin Genet 2011, 4:67-80.
148. Sharma M., Ioannidis J.P., Aasly J.O., Annesi G., Brice A., Van Broeckhoven C., Bertram L., Bozi M., Crosiers D., Clarke C., Facheris M., Farrer M., Garraux G., Gispert S., Auburger G., Vilarino-Guell C., Hadjigeorgiou G.M., Hicks A.A., Hattori N., Jeon B., Lesage S., Lill C.M., Lin J.J., Lynch T., Lichtner P., Lang A.E., Mok V., Jasinska-Myga B., Mellick G.D., Morrison K.E., Opala G., Pramstaller P.P., Pichler I., Park S.S., Quattrone A., Rogaeva E., Ross O.A., Stefanis L., Stockton J.D., Satake W., Silburn P.A., Theuns J., Tan E.K., Toda T., Tomiyama H., Uitti R.J., Wirdefeldt K., Wszolek Z., Xiromerisiou G., Yueh K.C., Zhao Y., Gasser T., Maraganore D., Kruger R. Large-scale replication and heterogeneity in Parkinson disease genetic loci. Neurology 2012, 79:659-667.
149. Sheng Z., Zhang S., Bustos D., Kleinheinz T., Le Pichon C.E., Dominguez S.L., Solanoy H.O., Drummond J., Zhang X., Ding X., Cai F., Song Q., Li X., Yue Z., van der Brug M.P., Burdick D.J., Gunzner-Toste J., Chen H., Liu X., Estrada A.A., Sweeney Z.K., Scearce-Levie K., Moffat J.G., Kirkpatrick D.S., Zhu H. Ser1292 autophosphorylation is an indicator of LRRK2 kinase activity and contributes to the cellular effects of PD mutations. Sci Transl Med 2012, 4:164ra161.
150. Shi F., Duan S., Cui J., Yan X., Li H., Wang Y., Chen F., Zhang L., Liu J., Xie X. Induction of matrix metalloproteinase-3 (MMP-3) expression in the microglia by lipopolysaccharide (LPS) via upregulation of glycoprotein nonmetastatic melanoma B (GPNMB) expression. J Mol Neurosci 2014.
151. Sidransky E., Nalls M.A., Aasly J.O., Aharon-Peretz J., Annesi G., Barbosa E.R., Bar-Shira A., Berg D., Bras J., Brice A., Chen C.M., Clark L.N., Condroyer C., De Marco E.V., Durr A., Eblan M.J., Fahn S., Farrer M.J., Fung H.C., Gan-Or Z., Gasser T., Gershoni-Baruch R., Giladi N., Griffith A., Gurevich T., Januario C., Kropp P., Lang A.E., Lee-Chen G.J., Lesage S., Marder K., Mata I.F., Mirelman A., Mitsui J., Mizuta I., Nicoletti G., Oliveira C., Ottman R., Orr-Urtreger A., Pereira L.V., Quattrone A., Rogaeva E., Rolfs A., Rosenbaum H., Rozenberg R., Samii A., Samaddar T., Schulte C., Sharma M., Singleton A., Spitz M., Tan E.K., Tayebi N., Toda T., Troiano A.R., Tsuji S., Wittstock M., Wolfsberg T.G., Wu Y.R., Zabetian C.P., Zhao Y., Ziegler S.G. Multicenter analysis of glucocerebrosidase mutations in Parkinson's disease. New Engl J Med 2009, 361:1651-1661.
152. Simon-Sanchez J., Schulte C., Bras J.M., Sharma M., Gibbs J.R., Berg D., Paisan-Ruiz C., Lichtner P., Scholz S.W., Hernandez D.G., Kruger R., Federoff M., Klein C., Goate A., Perlmutter J., Bonin M., Nalls M.A., Illig T., Gieger C., Houlden H., Steffens M., Okun M.S., Racette B.A., Cookson M.R., Foote K.D., Fernandez H.H., Traynor B.J., Schreiber S., Arepalli S., Zonozi R., Gwinn K., van der Brug M., Lopez G., Chanock S.J., Schatzkin A., Park Y., Hollenbeck A., Gao J., Huang X., Wood N.W., Lorenz D., Deuschl G., Chen H., Riess O., Hardy J.A., Singleton A.B., Gasser T. Genome-wide association study reveals genetic risk underlying Parkinson's disease. Nat Genet 2009, 41:1308-1312.
153. Spillantini M.G., Schmidt M.L., Lee V.M., Trojanowski J.Q., Jakes R., Goedert M. Alpha-synuclein in Lewy bodies. Nature 1997, 388:839-840.
154. Stevens C.H., Rowe D., Morel-Kopp M.C., Orr C., Russell T., Ranola M., Ward C., Halliday G.M. Reduced T helper and B lymphocytes in Parkinson's disease. J Neuroimmunol 2012, 252:95-99.
155. Stone D.K., Kiyota T., Mosley R.L., Gendelman H.E. A model of nitric oxide induced alpha-synuclein misfolding in Parkinson's disease. Neurosci Lett 2012, 523:167-173.
156. Su X., Maguire-Zeiss K.A., Giuliano R., Prifti L., Venkatesh K., Federoff H.J. Synuclein activates microglia in a model of Parkinson's disease. Neurobiol Aging 2008, 29:1690-1701.
157. Sun C., Wei L., Luo F., Li Y., Li J., Zhu F., Kang P., Xu R., Xiao L., Liu Z., Xu P. HLA-DRB1 alleles are associated with the susceptibility to sporadic Parkinson's disease in Chinese Han population. PloS One 2012, 7:e48594.
158. Sung H.Y., Park J.W., Kim J.S. The frequency and severity of gastrointestinal symptoms in patients with early Parkinson's disease. J Mov Disord 2014, 7:7-12.
159. Thevenet J., Pescini Gobert R., Hooft van Huijsduijnen R., Wiessner C., Sagot Y.J. Regulation of LRRK2 expression points to a functional role in human monocyte maturation. PloS One 2011, 6:e21519.
160. Tran T.A., Nguyen A.D., Chang J., Goldberg M.S., Lee J.K., Tansey M.G. Lipopolysaccharide and tumor necrosis factor regulate Parkin expression via nuclear factor-kappa B. PloS One 2011, 6:e23660.
161. Trudler D., Weinreb O., Mandel S.A., Youdim M.B., Frenkel D. DJ-1 deficiency triggers microglia sensitivity to dopamine toward a pro-inflammatory phenotype that is attenuated by rasagiline. J Neurochem 2014, 129:434-447.
162. Tschopp J. Mitochondria: sovereign of inflammation?. Eur J Immunol 2011, 41:1196-1202.
163. Umeno J., Asano K., Matsushita T., Matsumoto T., Kiyohara Y., Iida M., Nakamura Y., Kamatani N., Kubo M. Meta-analysis of published studies identified eight additional common susceptibility loci for Crohn's disease and ulcerative colitis. Inflamm Bowel Dis 2011, 17:2407-2415.
164. Valente E.M., Abou-Sleiman P.M., Caputo V., Muqit M.M., Harvey K., Gispert S., Ali Z., Del Turco D., Bentivoglio A.R., Healy D.G., Albanese A., Nussbaum R., Gonzalez-Maldonado R., Deller T., Salvi S., Cortelli P., Gilks W.P., Latchman D.S., Harvey R.J., Dallapiccola B., Auburger G., Wood N.W. Hereditary early-onset Parkinson's disease caused by mutations in PINK1. Science 2004, 304:1158-1160.
165. Van Limbergen J., Wilson D.C., Satsangi J. The genetics of Crohn's disease. Annu Rev Genom Hum Genet 2009, 10:89-116.
166. Vargas K.J., Makani S., Davis T., Westphal C.H., Castillo P.E., Chandra S.S. Synucleins regulate the kinetics of synaptic vesicle endocytosis. J Neurosci 2014, 34:9364-9376.
167. Vitner E.B., Farfel-Becker T., Eilam R., Biton I., Futerman A.H. Contribution of brain inflammation to neuronal cell death in neuronopathic forms of Gaucher's disease. Brain 2012, 135:1724-1735.
168. Vitner E.B., Salomon R., Farfel-Becker T., Meshcheriakova A., Ali M., Klein A.D., Platt F.M., Cox T.M., Futerman A.H. RIPK3 as a potential therapeutic target for Gaucher's disease. Nat Med 2014, 20:204-208.
169. Waak J., Weber S.S., Waldenmaier A., Gorner K., Alunni-Fabbroni M., Schell H., Vogt-Weisenhorn D., Pham T.T., Reumers V., Baekelandt V., Wurst W., Kahle P.J. Regulation of astrocyte inflammatory responses by the Parkinson's disease-associated gene DJ-1. FASEB J 2009, 23:2478-2489.
170. Walden H., Martinez-Torres R.J. Regulation of Parkin E3 ubiquitin ligase activity. Cell Mol Life Sci 2012, 69:3053-3067.
171. Watson M.B., Richter F., Lee S.K., Gabby L., Wu J., Masliah E., Effros R.B., Chesselet M.F. Regionally-specific microglial activation in young mice over-expressing human wildtype alpha-synuclein. Exp Neurol 2012, 237:318-334.
172. Weller C., Oxlade N., Dobbs S.M., Dobbs R.J., Charlett A., Bjarnason I.T. Role of inflammation in gastrointestinal tract in aetiology and pathogenesis of idiopathic parkinsonism. FEMS Immunol Med Microbiol 2005, 44:129-135.
173. West A.B., Moore D.J., Biskup S., Bugayenko A., Smith W.W., Ross C.A., Dawson V.L., Dawson T.M. Parkinson's disease-associated mutations in leucine-rich repeat kinase 2 augment kinase activity. Proc Natl Acad Sci USA 2005, 102:16842-16847.
174. Wilson M.A. The role of cysteine oxidation in DJ-1 function and dysfunction. Antioxid Redox Signal 2011, 15:111-122.
175. Wissemann W.T., Hill-Burns E.M., Zabetian C.P., Factor S.A., Patsopoulos N., Hoglund B., Holcomb C., Donahue R.J., Thomson G., Erlich H., Payami H. Association of Parkinson disease with structural and regulatory variants in the HLA region. Am J Hum Genet 2013, 93:984-993.
176. Wu J., Lei G., Mei M., Tang Y., Li H. A novel C53/LZAP-interacting protein regulates stability of C53/LZAP and DDRGK domain-containing Protein 1 (DDRGK1) and modulates NF-kappaB signaling. J Biol Chem 2010, 285:15126-15136.
177. Xi P., Ding D., Zhou J., Wang M., Cong Y.S. DDRGK1 regulates NF-kappaB activity by modulating IkappaBalpha stability. PloS One 2013, 8:e64231.
178. Yamayoshi S., Yamashita Y., Li J., Hanagata N., Minowa T., Takemura T., Koike S. Scavenger receptor B2 is a cellular receptor for enterovirus 71. Nat Med 2009, 15:798-801.
179. Yan Y., Laroui H., Ingersoll S.A., Ayyadurai S., Charania M., Yang S., Dalmasso G., Obertone T.S., Nguyen H., Sitaraman S.V., Merlin D. Overexpression of Ste20-related proline/alanine-rich kinase exacerbates experimental colitis in mice. J Immunol 2011, 187:1496-1505.
180. Yue Z., Yang X.W. Dangerous duet: LRRK2 and alpha-synuclein jam at CMA. Nat Neurosci 2013, 16:375-377.
181. Zhang D., Lin J., Han J. Receptor-interacting protein (RIP) kinase family. Cell Mol Immunol 2010, 7:243-249.
182. Zhang F.R., Huang W., Chen S.M., Sun L.D., Liu H., Li Y., Cui Y., Yan X.X., Yang H.T., Yang R.D., Chu T.S., Zhang C., Zhang L., Han J.W., Yu G.Q., Quan C., Yu Y.X., Zhang Z., Shi B.Q., Zhang L.H., Cheng H., Wang C.Y., Lin Y., Zheng H.F., Fu X.A., Zuo X.B., Wang Q., Long H., Sun Y.P., Cheng Y.L., Tian H.Q., Zhou F.S., Liu H.X., Lu W.S., He S.M., Du W.L., Shen M., Jin Q.Y., Wang Y., Low H.Q., Erwin T., Yang N.H., Li J.Y., Zhao X., Jiao Y.L., Mao L.G., Yin G., Jiang Z.X., Wang X.D., Yu J.P., Hu Z.H., Gong C.H., Liu Y.Q., Liu R.Y., Wang D.M., Wei D., Liu J.X., Cao W.K., Cao H.Z., Li Y.P., Yan W.G., Wei S.Y., Wang K.J., Hibberd M.L., Yang S., Zhang X.J., Liu J.J. Genomewide association study of leprosy. New Engl J Med 2009, 361:2609-2618.
183. Zhang Y., Viennois E., Xiao B., Baker M.T., Yang S., Okoro I., Yan Y. Knockout of Ste20-like proline/alanine-rich kinase (SPAK) attenuates intestinal inflammation in mice. Am J Pathol 2013, 182:1617-1628.
184. Zilka N., Kazmerova Z., Jadhav S., Neradil P., Madari A., Obetkova D., Bugos O., Novak M. Who fans the flames of Alzheimer's disease brains? Misfolded tau on the crossroad of neurodegenerative and inflammatory pathways. J Neuroinflamm 2012, 9:47.
185. Zimprich A., Biskup S., Leitner P., Lichtner P., Farrer M., Lincoln S., Kachergus J., Hulihan M., Uitti R.J., Calne D.B., Stoessl A.J., Pfeiffer R.F., Patenge N., Carbajal I.C., Vieregge P., Asmus F., Muller-Myhsok B., Dickson D.W., Meitinger T., Strom T.M., Wszolek Z.K., Gasser T. Mutations in LRRK2 cause autosomal-dominant Parkinsonism with pleomorphic pathology. Neuron 2004, 44:601-607.